Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	10/21/2008 9:29:30 AM
	Read Replies (1) of 10345

Biogen Idec Inc. posted a 73% rise in third-quarter net income, helped by strong sales of multiple-sclerosis drugs Avonex and Tysabri. The biotechnology firm reported net income of $206.8 million, or 70 cents a share, compared with $119.4 million, or 41 cents a share, a year earlier. Excluding acquisition-related and stock-compensation costs, earnings rose to 98 cents from 58 cents. Analysts surveyed by Thomson Reuters had expected earnings, excluding items, of 90 cents a share on revenue of $1.01 billion. Revenue rose 39% to $1.09 billion. Sales of Biogen's bestseller, Avonex, rose 26%, while the company's portion of sales from Tysabri nearly tripled. The balance goes to Biogen's partner on the drug, Elan Corp.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next